![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: INHBE |
Gene summary for INHBE |
![]() |
Gene information | Species | Human | Gene symbol | INHBE | Gene ID | 83729 |
Gene name | inhibin subunit beta E | |
Gene Alias | INHBE | |
Cytomap | 12q13.3 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | P58166 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83729 | INHBE | ATC11 | Human | Thyroid | ATC | 1.60e-07 | 1.00e+00 | 0.3386 |
83729 | INHBE | ATC3 | Human | Thyroid | ATC | 3.69e-12 | 8.98e-01 | 0.338 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000717823 | Thyroid | ATC | transmembrane receptor protein serine/threonine kinase signaling pathway | 170/6293 | 355/18723 | 1.40e-08 | 2.87e-07 | 170 |
GO:009009214 | Thyroid | ATC | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 120/6293 | 256/18723 | 6.62e-06 | 6.85e-05 | 120 |
GO:00901001 | Thyroid | ATC | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 51/6293 | 114/18723 | 8.62e-03 | 3.28e-02 | 51 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INHBE | SNV | Missense_Mutation | rs747468719 | c.839G>A | p.Cys280Tyr | p.C280Y | P58166 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
INHBE | SNV | Missense_Mutation | c.167A>C | p.His56Pro | p.H56P | P58166 | protein_coding | deleterious(0) | possibly_damaging(0.486) | TCGA-BH-A1ET-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
INHBE | SNV | Missense_Mutation | c.499N>T | p.Gly167Cys | p.G167C | P58166 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
INHBE | SNV | Missense_Mutation | rs533234507 | c.596N>A | p.Ser199Asn | p.S199N | P58166 | protein_coding | tolerated(0.48) | benign(0.027) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
INHBE | SNV | Missense_Mutation | rs759206435 | c.760N>A | p.Val254Ile | p.V254I | P58166 | protein_coding | tolerated(0.28) | benign(0.23) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
INHBE | SNV | Missense_Mutation | rs760258476 | c.1010C>T | p.Thr337Met | p.T337M | P58166 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
INHBE | SNV | Missense_Mutation | novel | c.71C>A | p.Ser24Tyr | p.S24Y | P58166 | protein_coding | deleterious(0.03) | possibly_damaging(0.776) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INHBE | SNV | Missense_Mutation | novel | c.703A>G | p.Arg235Gly | p.R235G | P58166 | protein_coding | deleterious(0) | benign(0.168) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INHBE | SNV | Missense_Mutation | c.241N>T | p.Pro81Ser | p.P81S | P58166 | protein_coding | tolerated(0.73) | benign(0.003) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
INHBE | SNV | Missense_Mutation | novel | c.21N>T | p.Gln7His | p.Q7H | P58166 | protein_coding | tolerated_low_confidence(0.06) | benign(0.204) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
83729 | INHBE | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | GNRH | GONADORELIN ACETATE | 8756531 |
Page: 1 |